Platelet-derived growth factor receptor alpha
Platelet-derived growth factor receptor alpha (PDGFRα) is a transmembrane receptor tyrosine kinase that plays a critical role in cellular growth, differentiation, and tissue development.
Platelet-derived growth factor receptor alpha (PDGFRα) is a transmembrane receptor tyrosine kinase that plays a critical role in cellular growth, differentiation, and tissue development. As a member of the class III receptor tyrosine kinase family, PDGFRα is activated by platelet-derived growth factors and regulates key signaling pathways including Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB) and mitogen-activated protein kinase (MAPK) cascades. The protein functions as a critical mediator of mesenchymal and stromal cell proliferation and is involved in normal developmental processes and tissue homeostasis. PDGFRα has become a significant therapeutic target in oncology due to its involvement in multiple cancer types, particularly those driven by gain-of-function mutations. The development of selective tyrosine kinase inhibitors targeting PDGFRα has established new treatment paradigms for otherwise difficult-to-treat malignancies.
Where the papers sit
12 papers from the last 6 months study platelet-derived growth factor receptor alpha directly · updated from PubMed 15 Nov 2026
Study type 0 clinical trials · 2 observational · 1 human data · 6 preclinical · 3 unclassified
Themes 3 themes
-
Fibrosis and Tumor Targeting
PDGFR-directed strategies appear across fibrosis imaging, nanotherapy, and experimental tumor treatment, but the subjects do not converge on one disease. Liver fibrosis work emphasizes miR149-5p control of PDGFRB and disruption of fibrosis–inflammation coupling. Other studies develop PDGFRB inhibitors or PET tracers for hepatocellular carcinoma and related tumors. The cluster also contains unrelated angiomyolipoma, urothelial carcinoma, and brain-tumor reports, so no shared therapeutic direction is established.
7 papers · 58.3%
-
PDGFRA-Mutant GIST
Genotyping is driving treatment selection in GIST, especially for PDGFRA-mutant disease. Structure-guided 6,7-quinazoline inhibitors aim to overcome KIT- and PDGFRA-mutation-driven resistance. Preoperative avapritinib can produce marked pathologic response in localized PDGFRA-mutant GIST, but standard dosing has limited feasibility. The open question is how to pair mutation-specific inhibition with tolerable perioperative treatment.
3 papers · 25%
-
PDGFRB-Linked Cancer Resensitization
Experimental cancer therapies are being used to restore drug sensitivity through PDGFRB-linked signaling and cell-death programs. Purine analogues promote autophagy-mediated apoptosis and can potentiate carboplatin, while wogonin resensitizes thyroid cancer through PDGFRB-dependent effects. Molecular docking and inhibition studies support target engagement, but evidence remains preclinical. Whether these mechanisms translate into durable responses or clinically useful combinations remains unresolved.
2 papers · 16.7%
Papers
The 12 papers from the last 6 months that study platelet-derived growth factor receptor alpha directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Fibrosis and Tumor Targeting (7)
- Mapping the Tissue Architecture and Endothelial-PEC Network in HAML Using Single-Cell and Spatial Transcriptomics. Cancer science · 7 Oct 2026 PMID 42841778
- Biodistribution and radiation dosimetry of the PDGFRβ targeting PET tracer [68Ga]Ga-ATH001. European journal of nuclear medicine and molecular imaging · 8 Sept 2026 PMID 42709070
- Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
- miR149-5p: A hepatocyte EXOmotif sequence containing microRNA that attenuates liver fibrosis by specifically targeting PDGFRB in HSCs. Journal of advanced research · 7 Aug 2026 PMID 42567345
- Intraoperative diagnosis of myxoid glioneuronal tumor guiding safe limited resection: a case report. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 1 Aug 2026 PMID 42542445
- Platelet-Derived Growth Factor Receptor α-Targeted Cell Membrane-Camouflaged Nanotherapy Disrupts Fibrosis-Inflammation Coupling in Intervertebral Disc Degeneration. ACS nano · 9 Jul 2026 PMID 42426566
- Discovery, Optimization, and Evaluation of Potent and Selective PDGFRβ Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of medicinal chemistry · 9 Jul 2026 PMID 42425901
PDGFRA-Mutant GIST (3)
- Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST. Nature communications · 6 Aug 2026 PMID 42562826
- Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing. Cancer medicine · 30 Jul 2026 PMID 42528110
- Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience. Anticancer research · 27 May 2026 PMID 42203307
PDGFRB-Linked Cancer Resensitization (2)
- Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer. Bioorganic chemistry · 2 Jul 2026 PMID 42391813
- Antitumor and resensitizing effects of wogonin in thyroid cancer via PDGFRB-dependent mechanisms. Phytomedicine : international journal of phytotherapy and phytopharmacology · 30 May 2026 PMID 42217345
By study type
Observational studies and case reports (2)
- Intraoperative diagnosis of myxoid glioneuronal tumor guiding safe limited resection: a case report. Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 1 Aug 2026 PMID 42542445
- Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing. Cancer medicine · 30 Jul 2026 PMID 42528110
Human data, design not indexed (1)
- Molecular Features of Gastrointestinal Stromal Tumors: A Single Referral Cancer Center Experience. Anticancer research · 27 May 2026 PMID 42203307
Preclinical: animal, cell and lab studies (6)
- Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
- Structure-based scaffold hopping reveals strategies to overcome oncogenic KIT and PDGFRA mutation-driven drug-resistance in GIST. Nature communications · 6 Aug 2026 PMID 42562826
- Platelet-Derived Growth Factor Receptor α-Targeted Cell Membrane-Camouflaged Nanotherapy Disrupts Fibrosis-Inflammation Coupling in Intervertebral Disc Degeneration. ACS nano · 9 Jul 2026 PMID 42426566
- Discovery, Optimization, and Evaluation of Potent and Selective PDGFRβ Inhibitors for the Treatment of Hepatocellular Carcinoma. Journal of medicinal chemistry · 9 Jul 2026 PMID 42425901
- Synthesis and biological evaluation of 6,9-disubstituted purine analogues inducing autophagy-mediated apoptosis and potentiating carboplatin response in high-grade serous ovarian cancer. Bioorganic chemistry · 2 Jul 2026 PMID 42391813
- Antitumor and resensitizing effects of wogonin in thyroid cancer via PDGFRB-dependent mechanisms. Phytomedicine : international journal of phytotherapy and phytopharmacology · 30 May 2026 PMID 42217345
Unclassified: not yet indexed with MeSH (3)
- Mapping the Tissue Architecture and Endothelial-PEC Network in HAML Using Single-Cell and Spatial Transcriptomics. Cancer science · 7 Oct 2026 PMID 42841778
- Biodistribution and radiation dosimetry of the PDGFRβ targeting PET tracer [68Ga]Ga-ATH001. European journal of nuclear medicine and molecular imaging · 8 Sept 2026 PMID 42709070
- miR149-5p: A hepatocyte EXOmotif sequence containing microRNA that attenuates liver fibrosis by specifically targeting PDGFRB in HSCs. Journal of advanced research · 7 Aug 2026 PMID 42567345
Written from 12 PubMed abstracts, each one listed by PMID above. Published: 2026-08-02. Last written: 2026-09-10 by GPT. Drafted by language models from published abstracts; not medical advice.